Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial

RCT (n=66) found that the addition of sofosbuvir and daclatasvir to standard care significantly reduced the duration of hospital stay vs standard care alone (6 days vs 8 days, p=0.029), but there was no statistically significant improvement in clinical recovery within 14 days.


Journal of Antimicrobial Chemotherapy